Hershey Gurjit K Khurana
Division of Allergy, and Immunology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, USA.
J Allergy Clin Immunol. 2003 Apr;111(4):677-90; quiz 691. doi: 10.1067/mai.2003.1333.
IL-13 is an immunoregulatory cytokine secreted predominantly by activated T(H)2 cells. Over the past several years, it has become evident that IL-13 is a key mediator in the pathogenesis of allergic inflammation. IL-13 shares many functional properties with IL-4, stemming from the fact that they share a common receptor subunit, the alpha subunit of the IL-4 receptor (IL-4Ralpha). Characterization of IL-13-deficient mice, IL-4-deficient mice, and IL-4 receptor alpha-deficient (IL-4Ralpha(-/-)) mice have demonstrated nonredundant roles for IL-13. IL-13 mediates its effects by interacting with a complex receptor system comprised of IL-4Ralpha and two IL-13 binding proteins, IL-13Ralpha1 and IL-13Ralpha2. IL-13 receptors are expressed on human B cells, basophils, eosinophils, mast cells, endothelial cells, fibroblasts, monocytes, macrophages, respiratory epithelial cells, and smooth muscle cells. However, functional IL-13 receptors have not been demonstrated on human or mouse T cells. Thus unlike IL-4, IL-13 does not appear to be important in the initial differentiation of CD4 T cells into T(H)2-type cells but rather appears to be important in the effector phase of allergic inflammation. This is further supported by many in vivo observations, including that administration of IL-13 resulted in allergic inflammation, tissue-specific overexpression of IL-13 in the lungs of transgenic mice resulted in airway inflammation and mucus hypersecretion, IL-13 blockade abolished allergic inflammation independently of IL-4, and IL-13 appears to be more important than IL-4 in mucus hypersecretion. Given the importance of IL-13 as an effector molecule, regulation at the level of its receptors might be an important mechanism of modulating IL-13 responses and thus propagation of the allergic response. Accordingly, IL-13 is an attractive, novel therapeutic target for pharmacologic intervention in allergic disorders. This review will summarize the current understanding of the IL-13 receptors and signaling pathways, emphasizing recent observations.
白细胞介素 -13(IL -13)是一种主要由活化的辅助性T细胞2(T(H)2)分泌的免疫调节细胞因子。在过去几年中,越来越明显的是,IL -13是过敏性炎症发病机制中的关键介质。IL -13与IL -4具有许多功能特性,这源于它们共享一个共同的受体亚基,即IL -4受体(IL -4Rα)的α亚基。对IL -13缺陷小鼠、IL -4缺陷小鼠和IL -4受体α缺陷(IL -4Rα(-/-))小鼠的特征研究表明,IL -13具有非冗余作用。IL -13通过与由IL -4Rα以及两种IL -13结合蛋白IL -13Rα1和IL -13Rα2组成的复杂受体系统相互作用来介导其效应。IL -13受体在人B细胞、嗜碱性粒细胞、嗜酸性粒细胞、肥大细胞、内皮细胞、成纤维细胞、单核细胞、巨噬细胞、呼吸道上皮细胞和平滑肌细胞上表达。然而,在人或小鼠T细胞上尚未证实存在功能性IL -13受体。因此,与IL -4不同,IL -13在CD4 T细胞初始分化为T(H)2型细胞过程中似乎并不重要,而在过敏性炎症的效应阶段似乎很重要。许多体内观察结果进一步支持了这一点,包括给予IL -13会导致过敏性炎症,转基因小鼠肺部组织特异性过表达IL -13会导致气道炎症和黏液分泌过多,阻断IL -13可独立于IL -4消除过敏性炎症,并且在黏液分泌过多方面IL -13似乎比IL -4更重要。鉴于IL -13作为效应分子的重要性,在其受体水平进行调节可能是调节IL -13反应从而控制过敏反应传播的重要机制。因此,IL -13是过敏性疾病药物干预中一个有吸引力的新型治疗靶点。本综述将总结目前对IL -13受体和信号通路的认识,重点强调近期的观察结果。